China Takes on Obesity! Mazdutide Puts Pressure on Novo Nordisk and Eli Lilly in Weight Loss Medications!
Reading Time: 4 minutes
The billion-dollar market for weight loss medications is facing competition from the Middle Kingdom. With Mazdutide, the Chinese biotech company Innovent Biologics has launched the world's first dual-action GCG/GLP-1 medication, achieving impressive results in studies. This could pose a real challenge for market leaders like Novo Nordisk (NVO) and Eli Lilly (LLY). Mazdutide is not only medically promising but also perfectly positioned economically and politically. Obesity in focus - a growing market for pharmaceutical giants Overweight and...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
